⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Kashiv BioSciences and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Kashiv BioSciences
↗Piscataway, New Jersey, USA
Kashiv BioSciences is a vertically integrated biopharmaceutical company specializing in the development and manufacturing of biosimilars and complex pharmaceutical products. The company maintains global R&D, clinical, and manufacturing capabilities with facilities in the United States (New Jersey) and India (Ahmedabad).
In April 2026, Kashiv BioSciences entered into a definitive agreement to be acquired by Amneal Pharmaceuticals, Inc. to strengthen their position as a global leader in the biosimilar market. The company focuses on high-quality standards for biologics, including monoclonal antibodies (mAbs), microbials, and fusion proteins.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Ownership:subsidiary
Status:acquired
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:mAb, Biologics, Peptides
Trial Phases:Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Amneal Pharmaceuticals, Inc.
Acquired By:Amneal Pharmaceuticals, Inc. (2026-04-01)
Key Partnerships:Intas Pharmaceuticals (Exclusive licensing and supply agreement for complex peptide product)
COMPETITION
Position:Challenger
LEADERSHIP
Key Executives:
Sandeep Athalye - Chief Executive Officer
LINKS
Website:kashivindia.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Kashiv BioSciences. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.